Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases.
Chord Therapeutics has raised €14M across 1 funding round from 1 investor, most recently a Series A round in Oct 2020. Based in Geneva, Switzerland; founded 2014; active in Healthtech. Acquired by Merck in 2021. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-10-13 | Series A | €14M | Omega Funds | View deal → |
